Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Carbamazepine on Ponesimod PK in Healthy Adults
NCT05552196Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ponesimod in multiple sclerosis (MS) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 22 and Area Under The Plasma Concentration-time Curve 0-24h at Day 22. Started Oct 2022; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05552196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552196.